抗人 STX2 抗体对
01AB00960
Syntaxin 2 (STX2) is a membrane-trafficking protein encoded by the STX2 gene, belonging to the syntaxin family of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. It plays a critical role in intracellular vesicle transport and membrane fusion, particularly in the Golgi apparatus and plasma membrane. Structurally, STX2 contains a C-terminal transmembrane domain and a conserved N-terminal SNARE motif, enabling interactions with other SNARE proteins to mediate vesicle docking and exocytosis. Its involvement in regulating secretory pathways and maintaining cellular homeostasis. STX2 is ubiquitously expressed, with higher levels observed in tissues like the pancreas and intestines. Its overexpression may contribute to cancer progression, including colorectal and breast cancers, by altering cell proliferation and metastasis pathways.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- STX2
- 基因别名
- EPIM; STX2A; STX2B; STX2C
- 蛋白别名
- syntaxin 2; STX2
- UniProt
- P32856
- 物种
- Human
产品详情
- 靶点名称
- STX2
- 蛋白名称
- syntaxin 2
- 蛋白别名
- Syntaxin-2; Epimorphin
- 靶点基因名
- STX2
- 基因别名
- EPIM; STX2A; STX2B; STX2C
- UniProt
- P32856
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Syntaxin 2 (STX2) is a membrane-trafficking protein encoded by the STX2 gene, belonging to the syntaxin family of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins. It plays a critical role in intracellular vesicle transport and membrane fusion, particularly in the Golgi apparatus and plasma membrane. Structurally, STX2 contains a C-terminal transmembrane domain and a conserved N-terminal SNARE motif, enabling interactions with other SNARE proteins to mediate vesicle docking and exocytosis. Its involvement in regulating secretory pathways and maintaining cellular homeostasis. STX2 is ubiquitously expressed, with higher levels observed in tissues like the pancreas and intestines. Its overexpression may contribute to cancer progression, including colorectal and breast cancers, by altering cell proliferation and metastasis pathways.